Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.64 |
| ▸ | CNR1 | P21554 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738838 | 0.89 | CNR2 (0.61) | CNR2CNR1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL735768 | 0.84 | CNR2 (0.62) | CNR2CNR1 | |
| SCHEMBL13588573 | 0.79 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL740358 | 0.78 | CNR2 (0.62) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL737821 | 0.78 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL739583 | 0.78 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL738109 | 0.77 | CNR2 (0.65) | CNR2CNR1TMEM97SIGMAR1 | |
| SCHEMBL14261219 | 0.75 | CNR2 (0.64) | CNR2CNR1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL739457 | 0.75 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL740106 | 0.75 | CNR2 (0.66) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885MEN1 2819/4885 |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885MEN1 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.